title: Anti-interleukin-17 treatment of psoriasis.
abstract: Psoriasis is a chronic, immune-mediated, inflammatory dermatosis, affecting 2-3% of the US population. While first-generation cytokine antagonists targeting tumor necrosis factor alpha (TNF-α)-dependent pathways have produced favorable responses in the treatment of psoriasis, higher levels of efficacy in a greater proportion of patients have been shown in trials with antibodies targeting interleukin (IL)-17A and the IL-17 receptor subunit. This examines the role of IL-17 inhibitors in the treatment of plaque psoriasis. The efficacy and safety results from the phase-3 trials with monoclonal antibodies targeting IL-17RA (brodalumab) and IL-17A (ixekizumab and secukinumab) validate IL-17 as a highly effective therapeutic target for the treatment of plaque psoriasis.
authors.affiliation: a Department of Dermatology , University of Connecticut School of Medicine , Farmington , CT , USA.
authors.forename: Sphoorthi
authors.initials: S
authors.lastname: Jinna
authors.affiliation: a Department of Dermatology , University of Connecticut School of Medicine , Farmington , CT , USA.
authors.forename: Bruce
authors.initials: B
authors.lastname: Strober
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors*; D011565:Psoriasis / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C508717:IL17A protein, human; D020381:Interleukin-17; C571216:brodalumab; C549079:ixekizumab; C555450:secukinumab
keywords: Brodalumab; IL-17; ixekizumab; psoriasis; secukinumab